Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
57 hedge funds and large institutions have $526M invested in Akcea Therapeutics Inc in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 10 closing their positions.
56% more capital invested
Capital invested by funds: $337M → $526M (+$189M)
19% more call options, than puts
Call options by funds: $1.52M | Put options by funds: $1.28M
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
2% less funds holding
Funds holding: 58 → 57 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$24.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.7M |
| 3 |
PA
Perceptive Advisors
New York
|
+$2.09M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.05M |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$814K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.27M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.37M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.99M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$1.74M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.21M |
AKCA Hedge Fund Activity: Q1 2018 in Review
57 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q1 2018, worth a combined $526M — up 56% from $337M a quarter earlier.
Fund positioning in AKCA was balanced in Q1 2018: 10 funds opened new positions, 10 closed out, 19 added to existing stakes and 21 trimmed.
The largest buyer was BB Biotech, adding an estimated $24.6M. The largest seller was Eventide Asset Management, cutting an estimated $5.27M.
- 57 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q1 2018, down from 58 in Q4 2017.
- Funds reported $526M of Akcea Therapeutics Inc stock for Q1 2018, up 56% quarter-over-quarter.
- 10 funds opened new Akcea Therapeutics Inc positions in Q1 2018 and 10 closed out, a net change of 0 holders.
- The largest Akcea Therapeutics Inc buyer in Q1 2018 was BB Biotech, an estimated $24.6M added.
- The largest Akcea Therapeutics Inc seller in Q1 2018 was Eventide Asset Management, an estimated $5.27M sold.
Based on aggregated 13F filings for Q1 2018.